Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
Samsung, Union Edge Closer to Deal as Strike Threat Looms 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
Elliott Targets Bio-Rad as Shares Continue to Struggle 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
SALT LAKE CITY, Sept. 20, 2016 -- Sera Prognostics, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Ladenburg Thalmann 2016 Healthcare Conference. Dr. Critchfield’s presentation will take place at 11:00 AM ET on Tuesday, September 27th, at the Sofitel Hotel in New York.
Sera Prognostics management will be available for one-on-one meetings with conference attendees during the day. To schedule a meeting with management, please contact Andrew Sauter, Chief Financial Officer at [email protected].
About Sera Prognostics, Inc.
Sera Prognostics, a women’s health company, develops innovative diagnostic tests focused on the early prediction of preterm birth (PTB) risk and other complications of pregnancy. Sera has launched its PreTRM® test, the first and only clinically validated blood test to accurately predict early in pregnancy the risk of premature birth. The test objectively reports to the physician the risk of premature delivery, enabling earlier proactive interventions designed to prolong gestation and improve neonatal health outcomes. Sera’s proprietary technology addresses both the health and economic challenges of PTB. Its strong management team has significant clinical development and women's healthcare diagnostic experience. Sera is backed by highly respected healthcare investors, including Domain Associates, InterWest Partners, Catalyst Health Ventures, and the Bill & Melinda Gates Foundation. Currently, Sera is working with the Gates Foundation to translate the Company’s discoveries into alternative technologies ideal for low-income countries in its journey to improve maternal and infant health globally. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company's website at www.seraprognostics.com.
Company Contact: Andrew Sauter Sera Prognostics [email protected] (801) 990-0772 Communications Contact Terri Clevenger Continuum Health Communications [email protected] (203)856-4326
